ElbasvirElbasvir is a drug approved by the FDA in January 2016 for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, used in combination with the NS3/4A protease inhibitor grazoprevir under the trade name Zepatier, either with or without ribavirin. Read from the Drugbox of the Wikipedia article Elbasvir, revision 1342170146.

Property

Value

Formula

C49H55N9O7, 882.03 g/mol

Protein binding

99.9 %

Elimination half-life

24 h

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.